Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. | Nat Biomed Eng | 2024 | 39420062 | PubTator, text mining | PubMed |
| DNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M). | Commun Biol | 2024 | 39390143 | PubTator, text mining | PubMed |
| Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cells. | EBioMedicine | 2024 | 39383607 | PubTator, text mining | PubMed |
| High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy. | Front Immunol | 2024 | 39364400 | PubTator, text mining | PubMed |
| Cancer immunotherapy by γδ T cells. | Science | 2024 | 39361750 | PubTator, text mining | PubMed |
| Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology. | Cells | 2024 | 39329700 | PubTator, text mining | PubMed |
| Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach. | J Extracell Biol | 2024 | 39328262 | PubTator, text mining | PubMed |
| CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies. | Semin Hematol | 2024 | 39306480 | PubTator, text mining | PubMed |
| "Predicting diabetic kidney disease in youth with type 1 diabetes: Insights from genetic risk assessment". | J Diabetes Complications | 2024 | 39293150 | PubTator, text mining | PubMed |
| Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies. | Blood Rev | 2024 | 39289094 | PubTator, text mining | PubMed |
| Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CAR NK cells. | Mol Ther Methods Clin Dev | 2024 | 39286335 | PubTator, text mining | PubMed |
| Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia. | J Hematol Oncol | 2024 | 39285441 | PubTator, text mining | PubMed |
| Liver-specific Coxsackievirus and adenovirus receptor deletion develop metabolic dysfunction-associated fatty liver disease. | Sci Rep | 2024 | 39285218 | PubTator, text mining | PubMed |
| Theoretical basis, state and challenges of living cell-based drug delivery systems. | Theranostics | 2024 | 39267776 | PubTator, text mining | PubMed |
| Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. | Biomed Pharmacother | 2024 | 39243430 | PubTator, text mining | PubMed |
| Different estimation techniques and data analysis for constant-partially accelerated life tests for power half-logistic distribution. | Sci Rep | 2024 | 39242750 | PubTator, text mining | PubMed |
| CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder. | Commun Biol | 2024 | 39217198 | PubTator, text mining | PubMed |
| Fast on-rates of chimeric antigen receptors enhance the sensitivity to peptide MHC via antigen rebinding. | J Biol Chem | 2024 | 39122001 | PubTator, text mining | PubMed |
| Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. | Lancet Haematol | 2024 | 39059405 | PubTator, text mining | PubMed |
| CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. | Nat Commun | 2024 | 39043633 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=6